Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

MLA

Kongnakorn T, et al. “Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives.” ClinicoEconomics and Outcomes Research, vol. ume 11, Nov. 2019, pp. 659–72. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.05ffa0ad64d4ab9bc91f472eae8250d&authtype=sso&custid=ns315887.

APA

Kongnakorn T, Bharmal M, Kearney M, Phatak H, Benedict A, Bhanegaonkar A, & Galsky M. (2019). Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives. ClinicoEconomics and Outcomes Research, ume 11, 659–672.

Chicago

Kongnakorn T, Bharmal M, Kearney M, Phatak H, Benedict A, Bhanegaonkar A, and Galsky M. 2019. “Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives.” ClinicoEconomics and Outcomes Research ume 11 (November): 659–72. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.05ffa0ad64d4ab9bc91f472eae8250d&authtype=sso&custid=ns315887.